Press Releases September 22, 2022Anticancer Bioscience named a finalist for China Biopharma Leadership Award by ScripRead MoreMay 18, 2022Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in OncologyRead MoreApril 19, 2022Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising LeaderRead MoreJanuary 17, 2022Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering TherapeuticsRead MoreJanuary 8, 2022Dr. Allen, VP of Anticancer Bioscience, Presented His Insights on Personalized / Precision Medicine at a Roundtable Discussion Organized by Pharma’s AlmanacRead MoreDecember 20, 2021Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, ChinaRead MoreOctober 25, 2021Anticancer Bioscience Has Been Named as One of the ‘50 Most Admired Companies Of The Year 2021’ By The Silicon ReviewRead MoreOctober 14, 2021Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31M to Advance Synthetic Lethality Approaches to Cancer TherapyRead MoreSeptember 9, 2021Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer TreatmentsRead MoreJuly 14, 2021Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical DevelopmentRead MoreMay 11, 2021Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in CancerRead MoreFebruary 8, 2021Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology PipelineRead MoreJanuary 12, 2021Anticancer Bioscience Presenting at Biotech Showcase™ Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First TimeRead More
